Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.

Study conducted to determine and compare the relative bioavailability of two solid oral formulations (reference versus test) of the non-fixed combination of Ticagrelor 90 mg (Brilinta by AstraZeneca S.A. de C.V.) + Acetylsalicylic Acid 100 mg (ASPIRINA JUNIOR by Bayer de México S.A. de C.V.) administered concomitantly versus the fixed-dose combination of Ticagrelor 90 mg / Acetylsalicylic Acid 100 mg manufactured by Laboratorios Silanes S.A. de C.V.

NCT Number	NCT07444164
Lead Sponsor	Laboratorios Silanes S.A. de C.V.
Conditions	Healthy
Enrollment	24 participants
Start Date	2025-01-13
Primary Completion	2025-01-23 (estimated)
Study Completion	2025-02-05 (estimated)
Updated on ClinicalTrials.gov	2026-03-02